argenx SE (ARGNF)

Market Cap	35.77B
Revenue (ttm)	1.91B
Net Income (ttm)	-40.29M
Shares Out	n/a
EPS (ttm)	-0.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	61
Open	540.00
Previous Close	n/a
Day's Range	525.60 - 540.00
52-Week Range	341.00 - 540.00
Beta	0.31
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2024

About argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1,148
• Stock Exchange: OTCMKTS
• Ticker Symbol: ARGNF

Financial Performance

In 2023, argenx SE's revenue was $1.27 billion, an increase of 187.66% compared to the previous year's $441.01 million. Losses were -$295.05 million, -58.42% less than in 2022.